



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade: 18.53

Trade Time: 11:49 AM ET
Dec 13, 2017

Change: 0.78 ↑
(+4.366%)

Day Range 17.70 - 18.53

52-Week Range 3.70 - 24.45

Volume 380,615

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Dec 5, 2017

[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Nov 27, 2017

[Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)

Nov 9, 2017

[Dynavax Announces FDA Approval of HEPLISAV-B\(TM\) for Prevention of Hepatitis B in Adults](#)

Nov 3, 2017

[Dynavax Reports Third Quarter 2017 Financial Results](#)

Oct 19, 2017

[Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017

[Annual Report \(10-K\)](#)

Jul 10, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 7, 2017

[Quarterly Report \(10-Q\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)